---
title: "Shanghai Runda Medical Technology Co., Ltd. (603108.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603108.SH.md"
symbol: "603108.SH"
name: "Shanghai Runda Medical Technology Co., Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T22:48:36.311Z"
locales:
  - [en](https://longbridge.com/en/quote/603108.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603108.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603108.SH.md)
---

# Shanghai Runda Medical Technology Co., Ltd. (603108.SH)

## Company Overview

Shanghai Runda Medical Technology Co., Ltd. provides medical laboratory services primarily in China. It offers laboratory design/renovation and SIMS stock information management system; medical solutions to help healthcare professionals; various customized laboratory management solutions; professional technical services; and logistic services. The company also engages in the research and development, manufacturing, sale, and service of in vitro diagnostic products, including reagents and other consumables.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.rundamedical.com](https://www.rundamedical.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.72)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 26 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.34% |  |
| Net Profit YoY | -1356.17% |  |
| P/B Ratio | 2.47 |  |
| Dividend Ratio | 0.20% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9113991672.52 |  |
| Revenue | 6859368970.32 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -13.30% | D |
| Profit Margin | -7.78% | D |
| Gross Margin | 23.24% | C |
| Revenue YoY | -13.34% | E |
| Net Profit YoY | -1356.17% | E |
| Total Assets YoY | -6.74% | D |
| Net Assets YoY | -12.72% | E |
| Cash Flow Margin | -106.39% | E |
| OCF YoY | -13.34% | E |
| Turnover | 0.50 | C |
| Gearing Ratio | 63.50% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Runda Medical Technology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-13.34%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1356.17%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.47",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.20%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9113991672.52",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "6859368970.32",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-13.30%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-7.78%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "23.24%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-13.34%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1356.17%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.74%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-12.72%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-106.39%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-13.34%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.50",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "63.50%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -17.52 | 20/26 | - | - | - |
| PB | 2.54 | 6/26 | 2.51 | 2.33 | 2.18 |
| PS (TTM) | 1.36 | 1/26 | 1.36 | 1.29 | 1.20 |
| Dividend Yield | 0.19% | 16/26 | 0.24% | 0.20% | 0.18% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | B | B | B |
| 03 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 04 | HitGen (688222.SH) | B | A | D | B | C | B |
| 05 | GEMPHARMATECH (688046.SH) | B | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-09-07T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.46 |
| Highest Target | 20.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603108.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603108.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603108.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603108.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**